Ftse Mib
38.421,05
0,00%
DAX
22.287,56
-0,24%
S&P 500
6.013,13
-1,71%
NASDAQ
19.524,01
-2,20%
Bitcoin
95.691,61
-0,60%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Prana Biotechnology Ltd ADS (PRAN) Prana Biotechnology Ltd ADS (PRAN) Notizie

PRAN

Prana Biotechnology Ltd ADS (PRAN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRAN
DataOraFonteTitoloSimboloCompagnia
31/01/201915:01Business WirePrana Receives First Orphan Drug Designation from the FDA for the Treatment of Multiple System AtrophyNASDAQ:PRANPrana Biotechnology Ltd ADS
02/01/201913:00PR Newswire (US)Life Biosciences LLC leads strategic investment of up to A$44.5 million (US$31.4 million) in PranaNASDAQ:PRANPrana Biotechnology Ltd ADS
05/10/201805:47Business WirePrana Biotechnology: Pre-Clinical Evidence Demonstrates PBT434 as a Potential Treatment for MSANASDAQ:PRANPrana Biotechnology Ltd ADS
04/09/201812:22Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:PRANPrana Biotechnology Ltd ADS
09/07/201802:15Business WirePBT434 Data to be Presented at the International Congress of Parkinson’s Disease and Movement DisordersNASDAQ:PRANPrana Biotechnology Ltd ADS
04/07/201803:38Business WireFirst Volunteers Dosed in Phase I Clinical Trial of PBT434, Prana’s Lead Therapy for Parkinsonian DiseasesNASDAQ:PRANPrana Biotechnology Ltd ADS
14/06/201802:55Business WirePrana to Commence Phase 1 Clinical Trial of PBT434 for Treatment of Parkinsonian DiseasesNASDAQ:PRANPrana Biotechnology Ltd ADS
18/07/201715:00Business WirePrana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal NeuropathologyNASDAQ:PRANPrana Biotechnology Ltd ADS
05/07/201715:00Business WirePrana's PBT434 Lowers Alpha-Synuclein and Prevents NeurodegenerationNASDAQ:PRANPrana Biotechnology Ltd ADS
05/06/201714:30Business WirePrana Appoints David Stamler as Chief Medical Officer to Lead Clinical DevelopmentNASDAQ:PRANPrana Biotechnology Ltd ADS
18/10/201617:00Business WireNew Data from Reach2HD Trial Presented at American Neurological Association Annual MeetingNASDAQ:PRANPrana Biotechnology Ltd ADS
27/07/201618:22Business WirePrana Alzheimer's disease data features at world leading conferenceNASDAQ:PRANPrana Biotechnology Ltd ADS
11/04/201614:00Business WirePrana Regains Compliance with NASDAQ Continued Listing Requirements Continues to Work Towards FDA SubmissionNASDAQ:PRANPrana Biotechnology Ltd ADS
26/02/201614:00Business WirePrana Biotechnology Half Year Investor ReportNASDAQ:PRANPrana Biotechnology Ltd ADS
16/11/201515:00Business WirePrana Chief Scientific Advisor Receives Smithsonian American Ingenuity AwardNASDAQ:PRANPrana Biotechnology Ltd ADS
09/11/201514:00Business WirePrana Receives Non-Compliance Notice Regarding NASDAQ Minimum Bid Price RequirementNASDAQ:PRANPrana Biotechnology Ltd ADS
27/08/201514:00Business WirePrana Reports FY15 Financial ResultsNASDAQ:PRANPrana Biotechnology Ltd ADS
24/07/201515:00PR Newswire (US)Technical Report on Drug Manufacturers - Other Stocks -- Synergy Pharma, Teva Pharma, Orexigen Therapeutics, Prana Biotechnol...NASDAQ:PRANPrana Biotechnology Ltd ADS
01/07/201505:58Business WirePrana Announces Safety Outcomes of Alzheimer’s IMAGINE Extension TrialNASDAQ:PRANPrana Biotechnology Ltd ADS
01/06/201519:21Business WireLa Commission européenne approuve la désignation orpheline pour le PBT2 dans le cadre de la maladie de HuntingtonNASDAQ:PRANPrana Biotechnology Ltd ADS
01/06/201517:20Business WireEuropäische Kommission gewährt PBT2 Orphan-Status für Chorea HuntingtonNASDAQ:PRANPrana Biotechnology Ltd ADS
01/06/201515:00Business WireEuropean Commission Approves PBT2 Orphan Designation for Huntington’s DiseaseNASDAQ:PRANPrana Biotechnology Ltd ADS
28/04/201505:22Business WirePBT2 Recommended for Orphan Designation in EuropeNASDAQ:PRANPrana Biotechnology Ltd ADS
19/11/201417:00Business WireThe Lancet Neurology Publishes Prana's Huntington Disease TrialNASDAQ:PRANPrana Biotechnology Ltd ADS
05/09/201415:49Dow Jones NewsU.S. Hot Stocks: Hot Stocks to WatchNASDAQ:PRANPrana Biotechnology Ltd ADS
05/09/201413:45PR Newswire (US)Prana receives FDA Orphan Drug Designation for PBT2 for Huntington DiseaseNASDAQ:PRANPrana Biotechnology Ltd ADS
17/07/201422:10PR Newswire (US)Prana Alzheimer's disease Development Program updateNASDAQ:PRANPrana Biotechnology Ltd ADS
14/05/201413:30PR Newswire (US)World leader in movement disorders Professor Ira Shoulson joins Prana BoardNASDAQ:PRANPrana Biotechnology Ltd ADS
23/04/201415:01Business WireZeldes Haeggquist & Eck LLP Announces Investigation of Prana Biotechnology LimitedNASDAQ:PRANPrana Biotechnology Ltd ADS
31/03/201423:03Dow Jones NewsMARKET SNAPSHOT: U.S. Stocks Rise; S&P 500, Nasdaq Notch Quarterly GainsNASDAQ:PRANPrana Biotechnology Ltd ADS
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PRAN

La tua Cronologia

BIT
UCG
Unicredit
BIT
STMMI
ST Microelectronics
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
CPR
Davide Campari
BIT
MONC
Moncler
BIT
RACE
Ferrari NV
BIT
PST
Poste Italiane S.p.a
BIT
BPE
Bper Banca
BIT
G
Generali
BIT
BAMI
Banco BPM
BIT
TIT
Telecom Italia
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci